Risk for second primary cancer higher in patients who smoked prior to first cancer
the ONA take:
A significant behavior that increases the risk of developing cancer is cigarette smoking. This fact has been proven in countless studies, and a recent pooled analysis of five prospective cohort studies indicates that the cancer risk goes beyond developing a first primary cancer.
The analysis shows that patients who smoked 20 or more cigarettes a day prior to a diagnosis of lung (stage I), bladder, kidney, or head and neck cancer were at increased risk of developing a second primary smoking-associated cancer compared with patients who had never smoked and had survived the same first cancers. The researchers note the second primary cancers are not metastases of the first cancer, but distinct new malignancies.
Smokers who smoked fewer than 20 cigarettes per day and former smokers who had quit before their first cancer diagnosis also were at higher risk of developing a second cancer. This is the first study to explore the risk of second primary cancers in current smokers.
Although further research is needed to assess the association between smoking after a first cancer and second cancer risk, these results further support encouraging smoking cessation to all patients who smoke.
A significant behavior that increases the risk of developing cancer is cigarette smoking.
Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers.
An analysis of five large, prospective cohort studies indicates that lung (stage I), bladder, kidney and head and neck cancer survivors who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to five-fold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|